The 10th Annual Johns Hopkins Dystonia & Spasticity Practicum Update: Toxin Treatment in the Managed Care Environment: Precertification, Medical Justification and Formulary
Presented by the Johns Hopkins University School of Medicine.
This activity is supported by educational grants and in-kind support from Allergan Inc, Ipsen Biopharmaceuticals Inc, and US WorldMeds, LLC.
Major support comes from Allergan Inc.
The cost of botulinum toxins to treat patients with dystonia and spasticity is one of the fastest growing healthcare expenditures. Currently, botulinum toxin therapies are the third most costly prior authorization for payors to manage. This educational activity will provide clinicians a comprehensive update regarding botulin toxin treatments in the managed care environment. Specifically, it will address precertifications and prior authorizations, medical justifications, and formulary decisions, as well as strategies to facilitate access to botulinum toxin therapies.
This activity is designed to meet the educational needs of neurology and physical medicine and rehabilitation residents and fellows, as well as community neurologists, physiatrists, physical, and occupational therapists. No prerequisites required.
After completing this activity, the participant will demonstrate the ability to:
- Describe patient- and provider-specific strategies for facilitating access to botulinum toxin therapy.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Toxin Treatment in the Managed Care Environment: Precertification, Medical Justification and Formulary
Fatta B. Nahab, MD
Chair and Planner
Zoltan Mari, MD
Associate Professor of Neurology
Director, Parkinson's and Movement Disorder Center
Director, National Parkinson Foundation Center of Excellence
Director, Movement Disorder Fellowship Program
Johns Hopkins University School of Medicine
Fatta B. Nahab, MD
Associate Professor of Neurosciences
Director, Functional Imaging of Neurodegenerative Disorders Laboratory
University of California, San Diego
San Diego, California
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. The following relationships have been reported for this activity:
Participating Faculty Disclosures
No faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
Dr Mari reports receiving grants/research support from AbbVie Inc and Avid Radiopharmaceuticals Inc; serving as principal investigator for Abbott Laboratories, Allergan Inc, and Merz Inc; serving as principal investigator for and receiving grants/research support from the National Institutes of Health, the National Parkinson Foundation, and The Michael J. Fox Foundation for Parkinson’s Research; and serving as a consultant for Ipsen Biopharmaceuticals, Medtronic, and Navidea Biopharmaceuticals.
No other planners have indicated that they have any financial interests or relationship with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
- 0.25 AMA PRA Category 1 Credit(s)™
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.
*Please be sure pop-ups are enabled.